411 материалов по теме, собраны автоматически из проверенных источников
UNC Study Develops Data-Driven Tool to Help Oncologists Identify High-Risk Periods for Metastatic Breast Cancer Patients UNC Health
AstraZeneca breast cancer drug fails late-stage trial goal Investing.com
AstraZeneca's breast cancer drug fails in late-stage trial KSL
Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer AstraZeneca
A research team at Huntsman Cancer Institute at the University of Utah (the U) has found that obesity prevents a biological process that kills cancerous cells, revealing a possible reason obesity is a risk factor for breast cancer.
Breast Cancer ADC Trials 2026: Critical PFS–OS Gap Revealed Oncodaily
A chemotherapy-free regimen offered durable disease control for certain patients with advanced breast cancer, according to results of the phase 1/phase 2 ASPIRE trial. The regimen — which consists of four targeted therapies — also appeared well tolerated, with no unexpected safety signals observed in a cohort of…
The COVID-19 pandemic accelerated the adoption of shorter-course radiation therapy for women with early-stage breast cancer, leading to reduced treatment burden and lower health care spending, according to a new study published in the American Journal of Clinical Oncology.
Two studies provide insights into the biological basis of triple-negative breast cancer ESMO Daily Reporter
Some advanced breast cancers stop responding to treatment. A new drug offers hope Newsweek
FDA Clears Prelude’s PRT13722 Phase 1 Trial in HR-Positive Breast Cancer The Clinical Trial Vanguard
An artificial intelligence model that analyzes women's past and recent annual 3D mammograms is more effective at predicting the five-year risk of developing breast cancer than a tool that uses only the most recent 3D mammogram, as well as an AI model that analyzes 2D mammograms, a new study shows.
Jasmin Hundal: Exploring How Treatment Reshapes Tumor Biology in HR+ Breast Cancer Oncodaily
Vepdegestrant Opens the PROTAC Era in Breast Cancer: Why Induced Proximity Matters Beyond ESR1 Oncodaily